...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Canadian journal of hospital pharmacy. >Rivaroxaban for a Patient with Class III Obesity: Case Report with Literature Review
【24h】

Rivaroxaban for a Patient with Class III Obesity: Case Report with Literature Review

机译：rivaroxaban为患有III类肥胖症的患者：案例报告与文献综述

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Between 1985 and 2011, the prevalence of obesity, defined as body mass index (BMI) of 30 kg/m2 or higher, increased from 6.1% to 18.3% in Canada. It is estimated that by 2019, more than 55% of the adult Canadian population will be overweight or obese.1 Obesity is associated with an approximately 2-fold increased risk of venous thromboembolism (VTE). The major mechanisms proposed as being responsible for obesity-associated thrombosis are chronic inflammation, impaired fibrinolysis, and clinical factors such as immobility, obstructive sleep apnea, heart failure, and venous stasis. Direct oral anticoagulants (DOACs) are indicated for the prevention of acute VTE in patients who have undergone elective hip or knee replacement, for the treatment of acute VTE, for the prevention of recurrent VTE, and for the prevention of stroke or systemic embolism in patients with atrial fibrillation. The Canadian rivaroxaban product monograph states that for patients with extremes of body weight (< 50 kg or > 120 kg), a 10-mg tablet caused less than a 25% change in the plasma concentration of rivaroxaban, and thus no dosage adjustment is required. The 2016 guidelines of the International Society on Thrombosis and Haemostasis (ISTH) suggest that DOACs not be used in patients with weight greater than 120 kg or BMI greater than 40 kg/m~2 because of the lack of clinical data for this population. We present here a case of rivaroxaban use in a patient with class III obesity and review the evidence for use of this medication in obese patients.
机译：介绍：1985年至2011年间，肥胖的患病率，定义为30公斤/平方米或更高的体重指数（BMI），从加拿大的6.1％增加到18.3％。据估计，到2019年，超过55％的成人加拿大人口将超重或肥胖的肥胖与静脉血栓栓塞（VTE）的风险大约2倍。拟议的主要机制作为肥胖相关血栓形成的负责是慢性炎症，纤维蛋白溶解，临床因素，如不动，阻塞性睡眠呼吸暂停，心力衰竭和静脉痉挛等临床因素。直接口服抗凝血剂（DoAC）用于预防受到选择性髋关节或膝关节或膝关节置换的患者的急性VTE，用于治疗急性VTE，用于预防复发性VTE，以及预防患者中风或全身栓塞心房颤动。加拿大Rivaroxaban产品专着表明，对于极端体重（<50千克或120kg）的患者，10毫升的片剂引起蓖麻血清血浆浓度的25％变化，因此不需要剂量调节。 2016年国际血栓形成和呼吸症协会（ISTH）的指导方针表明，由于缺乏该人群的临床数据，减肥患者的患者不得用于大于40kg / m〜2的患者。我们在这里展示了患有III类肥胖症的患者的稻草爪班，并审查了在肥胖患者使用这种药物的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号